Cargando…
Ibrutinib-Associated Cardiac Tamponade with Concurrent Antiplatelet Therapy
Ibrutinib is approved for the first-line treatment of chronic lymphocytic leukemia (CLL). A well-known side effect of ibrutinib therapy is increased bleeding risk, which ranges from mild mucocutaneous bleeding to rarely life-threatening hemorrhage. The increased bleeding tendency associated with ibr...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139853/ https://www.ncbi.nlm.nih.gov/pubmed/32280549 http://dx.doi.org/10.1155/2020/4282486 |